Lead Product(s): CAR-T Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Casdin Capital
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 16, 2021
The Series A financing will allow the company to accelerate development of the EnfiniT targeting and next generation chimeric antigen receptors (CAR) T cell therapy platform combining the pioneering research from Institut Curie and Memorial Sloan Kettering Cancer Center.